# enVVeno Medical Corp: financial statements, quarterly

NVNO · Nasdaq · CIK 1661053 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/nvno.md) · [Financials](/companies/nvno/financials.md) · [Filings](/companies/nvno/filings.md) · [Insiders](/companies/nvno/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/nvno/financials.md?period=annual).

## Income statement

| Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Cost of revenue | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Gross profit | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $k | [2,981 d](/filings/0001493152-25-008739.md) | [3,052](/filings/0001641172-25-007908.md) | [2,825](/filings/0001493152-25-011521.md) | [2,859](/filings/0001493152-25-020215.md) | [3,513 d](/filings/0001493152-26-012928.md) | [2,557](/filings/0001493152-26-021490.md) | [2,891](/filings/0001493152-26-035452.md) | [2,585](/filings/0001493152-26-049269.md) | [1,948 d](/filings/0001493152-26-012928.md) | [2,111](/filings/0001493152-26-021490.md) | [2,076](/filings/0001493152-26-035452.md) | [2,876](/filings/0001493152-26-049269.md) |
| Selling, general and administrative | $k | [3,297 d](/filings/0001493152-25-008739.md) | [2,451](/filings/0001641172-25-007908.md) | [2,629](/filings/0001493152-25-011521.md) | [3,311](/filings/0001493152-25-020215.md) | [3,186 d](/filings/0001493152-26-012928.md) | [2,397](/filings/0001493152-26-021490.md) | [4,158](/filings/0001493152-26-035452.md) | [2,298](/filings/0001493152-26-049269.md) | [2,065 d](/filings/0001493152-26-012928.md) | [1,951](/filings/0001493152-26-021490.md) | [1,720](/filings/0001493152-26-035452.md) | [1,658](/filings/0001493152-26-049269.md) |
| Operating income | $k | [(6,278) d](/filings/0001493152-25-008739.md) | [(5,503)](/filings/0001641172-25-007908.md) | [(5,454)](/filings/0001493152-25-011521.md) | [(6,170)](/filings/0001493152-25-020215.md) | [(6,699) d](/filings/0001493152-26-012928.md) | [(4,954)](/filings/0001493152-26-021490.md) | [(7,049)](/filings/0001493152-26-035452.md) | [(4,883)](/filings/0001493152-26-049269.md) | [(4,013) d](/filings/0001493152-26-012928.md) | [(4,062)](/filings/0001493152-26-021490.md) | [(3,796)](/filings/0001493152-26-035452.md) | [(4,534)](/filings/0001493152-26-049269.md) |
| Net income | $k | [(5,649) d](/filings/0001493152-25-008739.md) | [(4,992)](/filings/0001641172-25-007908.md) | [(4,956)](/filings/0001493152-25-011521.md) | [(5,642)](/filings/0001493152-25-020215.md) | [(6,229) d](/filings/0001493152-26-012928.md) | [(4,503)](/filings/0001493152-26-021490.md) | [(6,694)](/filings/0001493152-26-035452.md) | [(4,539)](/filings/0001493152-26-049269.md) | [(3,736) d](/filings/0001493152-26-012928.md) | [(3,849)](/filings/0001493152-26-021490.md) | [(3,600)](/filings/0001493152-26-035452.md) | [(4,367)](/filings/0001493152-26-049269.md) |
| Diluted EPS | $ per share | not reported | [(0.31)](/filings/0001641172-25-007908.md) | [(0.31)](/filings/0001493152-25-011521.md) | [(0.35)](/filings/0001493152-25-020215.md) | not reported | [(7.75)](/filings/0001493152-26-021490.md) | [(11.52)](/filings/0001493152-26-035452.md) | [(7.89)](/filings/0001493152-26-049269.md) | not reported | [(5.89)](/filings/0001493152-26-021490.md) | [(5.37)](/filings/0001493152-26-035452.md) | [(6.29)](/filings/0001493152-26-049269.md) |
| Basic EPS | $ per share | not reported | [(0.31)](/filings/0001641172-25-007908.md) | [(0.31)](/filings/0001493152-25-011521.md) | [(0.35)](/filings/0001493152-25-020215.md) | not reported | [(7.75)](/filings/0001493152-26-021490.md) | [(11.52)](/filings/0001493152-26-035452.md) | [(7.89)](/filings/0001493152-26-049269.md) | not reported | [(5.89)](/filings/0001493152-26-021490.md) | [(5.37)](/filings/0001493152-26-035452.md) | [(6.29)](/filings/0001493152-26-049269.md) |

- Revenue: not reported
- Cost of revenue: not reported
- Gross profit: not reported
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [3.6](/filings/0001493152-25-008739.md) | [2.3](/filings/0001493152-24-018225.md) | [2.4](/filings/0001493152-24-029737.md) | [17.9](/filings/0001493152-24-043100.md) | [1.8](/filings/0001493152-26-012928.md) | [2.9](/filings/0001641172-25-007908.md) | [2.0](/filings/0001493152-25-011521.md) | [1.5](/filings/0001493152-25-020215.md) | [3.1](/filings/0001493152-26-049269.md) | [2.6](/filings/0001493152-26-021490.md) | [2.8](/filings/0001493152-26-035452.md) | [2.6](/filings/0001493152-26-049269.md) |
| Current assets | $m | [46.9](/filings/0001493152-25-008739.md) | [43.2](/filings/0001493152-24-018225.md) | [39.5](/filings/0001493152-24-029737.md) | [49.1](/filings/0001493152-24-043100.md) | [43.7](/filings/0001493152-26-012928.md) | [39.5](/filings/0001641172-25-007908.md) | [35.6](/filings/0001493152-25-011521.md) | [31.5](/filings/0001493152-25-020215.md) | [28.8](/filings/0001493152-26-049269.md) | [25.5](/filings/0001493152-26-021490.md) | [22.1](/filings/0001493152-26-035452.md) | [19.0](/filings/0001493152-26-049269.md) |
| Total assets | $m | [48.6](/filings/0001493152-25-008739.md) | [44.8](/filings/0001493152-24-018225.md) | [41.0](/filings/0001493152-24-029737.md) | [50.4](/filings/0001493152-24-043100.md) | [45.0](/filings/0001493152-26-012928.md) | [40.6](/filings/0001641172-25-007908.md) | [36.6](/filings/0001493152-25-011521.md) | [32.4](/filings/0001493152-25-020215.md) | [29.6](/filings/0001493152-26-049269.md) | [26.1](/filings/0001493152-26-021490.md) | [22.7](/filings/0001493152-26-035452.md) | [19.5](/filings/0001493152-26-049269.md) |
| Current liabilities | $m | [1.4](/filings/0001493152-25-008739.md) | [1.5](/filings/0001493152-24-018225.md) | [1.7](/filings/0001493152-24-029737.md) | [2.2](/filings/0001493152-24-043100.md) | [2.1](/filings/0001493152-26-012928.md) | [1.7](/filings/0001641172-25-007908.md) | [3.0](/filings/0001493152-25-011521.md) | [2.4](/filings/0001493152-25-020215.md) | [2.1](/filings/0001493152-26-049269.md) | [2.1](/filings/0001493152-26-021490.md) | [1.9](/filings/0001493152-26-035452.md) | [2.6](/filings/0001493152-26-049269.md) |
| Total liabilities | $m | [2.4](/filings/0001493152-25-008739.md) | [2.5](/filings/0001493152-24-018225.md) | [2.6](/filings/0001493152-24-029737.md) | [3.0](/filings/0001493152-24-043100.md) | [2.8](/filings/0001493152-26-012928.md) | [2.3](/filings/0001641172-25-007908.md) | [3.5](/filings/0001493152-25-011521.md) | [2.9](/filings/0001493152-25-020215.md) | [2.4](/filings/0001493152-26-049269.md) | [2.4](/filings/0001493152-26-021490.md) | [2.0](/filings/0001493152-26-035452.md) | [2.6](/filings/0001493152-26-049269.md) |
| Shareholders' equity | $m | [46.2](/filings/0001493152-26-012928.md) | [42.4](/filings/0001493152-25-011521.md) | [38.4](/filings/0001493152-25-020215.md) | [47.4](/filings/0001493152-25-020215.md) | [42.2](/filings/0001493152-26-049269.md) | [38.3](/filings/0001493152-26-035452.md) | [33.1](/filings/0001493152-26-049269.md) | [29.4](/filings/0001493152-26-049269.md) | [27.1](/filings/0001493152-26-049269.md) | [23.7](/filings/0001493152-26-035452.md) | [20.7](/filings/0001493152-26-049269.md) | [16.9](/filings/0001493152-26-049269.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(4,973) d](/filings/0001493152-25-008739.md) | [(3,550)](/filings/0001641172-25-007908.md) | [(3,907) d](/filings/0001493152-25-011521.md) | [(4,276) d](/filings/0001493152-25-020215.md) | [(5,105) d](/filings/0001493152-26-012928.md) | [(4,018)](/filings/0001493152-26-021490.md) | [(3,715) d](/filings/0001493152-26-035452.md) | [(4,392) d](/filings/0001493152-26-049269.md) | [(3,443) d](/filings/0001493152-26-012928.md) | [(3,238)](/filings/0001493152-26-021490.md) | [(3,549) d](/filings/0001493152-26-035452.md) | [(3,178) d](/filings/0001493152-26-049269.md) |
| Capital expenditure | $k | [4.0 d](/filings/0001493152-25-008739.md) | [10.0](/filings/0001641172-25-007908.md) | [14.0 d](/filings/0001493152-25-011521.md) | [9.0 d](/filings/0001493152-25-020215.md) | [4.0 d](/filings/0001493152-26-012928.md) | not reported | not reported | [0.0 d](/filings/0001493152-26-049269.md) | [0.0 d](/filings/0001493152-26-012928.md) | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [11.2](/filings/0001493152-24-018225.md) | [11.2](/filings/0001493152-24-029737.md) | [11.2](/filings/0001493152-24-043100.md) | [16.1](/filings/0001641172-25-007908.md) | [16.1](/filings/0001493152-25-011521.md) | [16.1](/filings/0001493152-25-020215.md) | [0.6](/filings/0001493152-26-021490.md) | [0.6](/filings/0001493152-26-035452.md) | [0.6](/filings/0001493152-26-049269.md) | [0.7](/filings/0001493152-26-021490.md) | [0.7](/filings/0001493152-26-035452.md) | [0.7](/filings/0001493152-26-049269.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 694,826 at 2026-10-27, from the cover of the [10-Q filed 2026-10-29](/filings/0001493152-26-049269.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 29, 2026, 19:27 ET. No prices; not investment advice.